| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Interim CEO &General Counsel
1 company
Vogt Frederick G serves as an Interim CEO &General Counsel at IOVA. Across recent SEC filings that breaks down to 3 buys and 0 sells. Those positions are worth an estimated $2.9M at current prices.
Historically, Vogt Frederick G's trades have earned a middling insider score of 59/100 across 3 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +15.2%.
The biggest single holding is IOVA (~$2.9M) as Interim CEO &General Counsel. Net of sales, the recent Form 4 record there shows accumulation of 27,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2025 | IOVA Iovance Biotherapeutics, Inc. | Interim CEO &General Counsel | Buy | 25,000 | $1.69 | $42,250.00 | +7.2% | +30.8% | - | |
| Nov 28, 2022 | IOVA Iovance Biotherapeutics, Inc. | Interim CEO &General Counsel | Buy | 1,000 | $5.98 | $5,980.00 | +100.0% | +20.5% | -6.4% | |
| Jun 1, 2022 | IOVA Iovance Biotherapeutics, Inc. | Interim CEO &General Counsel | Buy | 1,000 | $6.44 | $6,440.00 | New | +63.8% | +36.8% |